Les résultats de cette étude mettent en évidence le rôle complexe du microbiome* intestinal et de l’épithélium* intestinal dans la progression de la SLA, et présentent le butyrate* comme un réactif thérapeutique potentiel pour restaurer la dysbiose* liée à la SLA.

Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis

Emerging evidence has demonstrated that gut microbiome plays essential roles in the pathogenesis of human diseases in distal organs. Amyotrophic lateral sclerosis ( ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. Treatment with the only drug approved by the US Food and Drug Administration for use in ALS, riluzole, extends a patient׳s life span by only a few months. Thus, there is an urgent need to develop novel interventions that for alleviate disease progression and improve quality of life in patients with ALS.

www.clinicaltherapeutics.com